Home > Journals > Minerva Urology and Nephrology > Past Issues > Minerva Urologica e Nefrologica 2017 October;69(5) > Minerva Urologica e Nefrologica 2017 October;69(5):409-20

CURRENT ISSUE
 

JOURNAL TOOLS

Publishing options
eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

REVIEW   Free accessfree

Minerva Urologica e Nefrologica 2017 October;69(5):409-20

DOI: 10.23736/S0393-2249.16.02726-0

Copyright © 2016 EDIZIONI MINERVA MEDICA

language: English

Basic methods for the assessment of health-related quality of life in uro-oncological patients

Roman SOSNOWSKI 1 , Marta KULPA 2, Mariola KOSOWICZ 2, Fabrizio PRESICCE 3, Francesco PORPIGLIA 4, Andrea TUBARO 3, Cosimo DE NUNZIO 3, Tomasz DEMKOW 1

1 Department of Uro-Oncology, M. Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland; 2 Department of Psycho-Oncology, M. Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland; 3 Department of Urology, Sant’Andrea Hospital, “Sapienza” University of Rome, Rome, Italy; 4 Division of Urology, Department of Oncology, University of Turin, Turin, Italy


PDF


BACKGROUND: The evaluation of patients’ expectations and quality of life in uro-oncology is considered an important outcome of treatment efficacy and satisfaction. Aim of this systematic review was to evaluate the most frequently adopted tools in uro-oncology to assess Health Related Quality of Life (HRQoL).
EVIDENCE ACQUISITION: A systematic literature search until October 2015 was performed on MEDLINE, Cochrane Library, PubMed combining the following terms: “quality of life,” “health-related quality of life,” “kidney cancer,” “bladder cancer,” “prostate cancer.” Additional references were obtained from the reference list of full-text manuscripts. Data were synthesized using meta-analytic methods conformed to the PRISMA statement.
EVIDENCE SYNTHESIS: HRQoL is a fundamental step in evaluating treatment outcome in patients with urological cancers. HRQoL is mostly measured through several questionnaires, which are generally categorized in generic questionnaires, exploring the patient’s well-being en bloc; specific questionnaires, assessing each single domain of health status; and uro-oncological specific questionnaires, mainly characterized by a modular approach. Although different questionnaires have been proposed and validated, the standard method to be adopted in urology is far from the solution and further studies should investigate the strength and weakness of the different questionnaires.
CONCLUSIONS: HRQoL questionnaires should become a standard method to evaluate medical/surgical outcomes in uro-oncology. Their implementation may significantly improve patients’ satisfaction and help physicians in the decision-making process and possibly reduce health care costs.


KEY WORDS: Quality of life - Urinary bladder neoplasms - Prostatic neoplasms - Kidney neoplasms

top of page